CY1105557T1 - Θεραπεια της σχιζοφρενειας με αμπακινες και νευροληπτικα φαρμακα - Google Patents

Θεραπεια της σχιζοφρενειας με αμπακινες και νευροληπτικα φαρμακα

Info

Publication number
CY1105557T1
CY1105557T1 CY20061100571T CY061100571T CY1105557T1 CY 1105557 T1 CY1105557 T1 CY 1105557T1 CY 20061100571 T CY20061100571 T CY 20061100571T CY 061100571 T CY061100571 T CY 061100571T CY 1105557 T1 CY1105557 T1 CY 1105557T1
Authority
CY
Cyprus
Prior art keywords
schizophrenia
treatment
drugs
neuroceptive
ampacines
Prior art date
Application number
CY20061100571T
Other languages
English (en)
Inventor
Steven A. Johnson
Gary A. Rogers
Gary S. Lynch
Original Assignee
Cortex Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22050462&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1105557(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cortex Pharmaceuticals, Inc. filed Critical Cortex Pharmaceuticals, Inc.
Publication of CY1105557T1 publication Critical patent/CY1105557T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Η παρούσα εφεύρεση σχετίζεται με την θεραπεία της σχιζοφρένειας και σχετικών ψυχωτικών διαταραχών, συμπεριλαμβανομένης και της ενίσχυσης της λειτουργίας του υποδοχέα στη σύναψη στα εγκεφαλικά δίκτυα που είναι υπεύθυνα για ανώτερες συμπεριφορές. Από μια συγκεκριμένη οπτική γωνία, η παρούσα εφεύρεση σχετίζεται με μεθόδους που αφορούν τη χρήση των ενισχυτών του υποδοχέα ΑΜΡΑ σε σύζευξη με αντιψυχωτικά φάρμακα για τη θεραπεία της σχιζοφρένειας. Επίσης παρέχονται κιτία που περιέχουν τις συνθέσεις σε κατάλληλη προς χορήγηση μορφή. Το Σχήμα δείχνει ότι μια αντιπροσωπευτική Αμπακίνη (CX516) τονίζει συνεργιστικά τον ανταγωνισμό της κλοζαπίνης με την δραστηριότητα παλινδρόμησης της επαγόμενης μεταμφεταμίνης.
CY20061100571T 1997-10-27 2006-05-04 Θεραπεια της σχιζοφρενειας με αμπακινες και νευροληπτικα φαρμακα CY1105557T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6362797P 1997-10-27 1997-10-27
PCT/US1998/022707 WO1999021422A1 (en) 1997-10-27 1998-10-26 Treatment of schizophrenia with ampakines and neuroleptics

Publications (1)

Publication Number Publication Date
CY1105557T1 true CY1105557T1 (el) 2010-07-28

Family

ID=22050462

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20061100571T CY1105557T1 (el) 1997-10-27 2006-05-04 Θεραπεια της σχιζοφρενειας με αμπακινες και νευροληπτικα φαρμακα

Country Status (15)

Country Link
US (1) US6166008A (el)
EP (1) EP1026950B1 (el)
JP (1) JP2001520978A (el)
CN (1) CN1281335A (el)
AT (1) ATE317226T1 (el)
AU (1) AU745641B2 (el)
BR (1) BR9814106A (el)
CA (1) CA2306817A1 (el)
CY (1) CY1105557T1 (el)
DE (1) DE69833451T2 (el)
DK (1) DK1026950T3 (el)
ES (1) ES2258825T3 (el)
HK (1) HK1030338A1 (el)
PT (1) PT1026950E (el)
WO (1) WO1999021422A1 (el)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2450801C (en) 1992-07-24 2009-11-17 The Regent Of The University Of California Drugs that enhance synaptic responses mediated by ampa receptors
WO2002096431A1 (en) * 2001-05-25 2002-12-05 The Regents Of The University Of California Optically active compounds clearing malformed proteins
US20040229898A1 (en) * 2001-05-25 2004-11-18 The Regents Of The University Of California Cyclic bis-compounds clearing malformed proteins
JP2004538323A (ja) * 2001-08-10 2004-12-24 ザ ロックフェラー ユニバーシティー Ｄａｒｐｐ−３２リン酸化のモジュレーションのための組成物及び方法
US20060276462A1 (en) * 2003-01-13 2006-12-07 Deadwyler Sam A Method of treating cognitive decline due to sleep deprivation and stress
WO2005013961A1 (en) * 2003-07-17 2005-02-17 Eli Lilly And Company Combination therapy for treatment of cognitive disorders or psychoses
NZ527142A (en) * 2003-07-23 2006-03-31 Douglas Pharmaceuticals Ltd A stable suspension formulation
JP2007504136A (ja) 2003-08-28 2007-03-01 ニトロメッド インコーポレーティッド ニトロソ化およびニトロシル化利尿化合物、組成物、ならびに使用方法
GB0325175D0 (en) * 2003-10-28 2003-12-03 Novartis Ag Organic compounds
JP2007519733A (ja) * 2004-01-26 2007-07-19 コーテックス ファーマシューティカルズ インコーポレーティッド アンパカインにより誘導されるシナプス応答促通のコリンエステラーゼ阻害剤による増強方法
EP2453024B1 (en) 2004-06-21 2017-12-06 The Board of Trustees of The Leland Stanford Junior University Genes and pathways differentially expressed in bipolar disorder and/or major depressive disorder
WO2006034196A1 (en) * 2004-09-17 2006-03-30 Lifelike Biomatic Inc. Compositions for enhancing memory and methods therefor
EP1809104A4 (en) * 2004-09-23 2009-04-29 Alexander Michalow METHODS FOR REGULATING NEUROTRANSMITTER SYSTEMS BY INDUCING COUNTER-ADAPTATIONS
EP1855688A4 (en) * 2005-02-24 2011-09-14 Nicox Sa NON-STAINED OXIDE DIURETIC COMPOUNDS, COMPOSITIONS AND USE PROCESSES
TWI378090B (en) 2005-04-13 2012-12-01 Astex Therapeutics Ltd Pharmaceutical compounds
KR20060119373A (ko) * 2005-05-20 2006-11-24 엘지전자 주식회사 컴퓨터 시스템과 시스템 소프트웨어 설치방법 및 휴대용컴퓨터의 소프트웨어 설치방법
US20090019557A1 (en) 2005-11-12 2009-01-15 Huda Akil Fgf2-related methods for diagnosing and treating depression
US20090286797A1 (en) * 2005-11-22 2009-11-19 Dan Peters Novel Quinoxaline Derivatives and Their Medical Use
US7754725B2 (en) 2006-03-01 2010-07-13 Astex Therapeutics Ltd. Dihydroxyphenyl isoindolymethanones
US20080176793A1 (en) * 2006-09-18 2008-07-24 The Regents Of The University Of California Upregulating activity or expression of bdnf to mitigate cognitive impairment in asymptomatic huntington's subjects
JP5721949B2 (ja) 2006-10-12 2015-05-20 アステックス、セラピューティックス、リミテッドＡｓｔｅｘ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ 複合薬剤
GB0620259D0 (en) 2006-10-12 2006-11-22 Astex Therapeutics Ltd Pharmaceutical compounds
WO2008044041A1 (en) 2006-10-12 2008-04-17 Astex Therapeutics Limited Pharmaceutical combinations
EP2073807A1 (en) 2006-10-12 2009-07-01 Astex Therapeutics Limited Pharmaceutical combinations
WO2008044027A2 (en) 2006-10-12 2008-04-17 Astex Therapeutics Limited Pharmaceutical compounds having hsp90 inhibitory or modulating activity
JP5518478B2 (ja) 2006-10-12 2014-06-11 アステックス、セラピューティックス、リミテッド 医薬化合物
US8198305B2 (en) * 2007-04-13 2012-06-12 Concert Pharmaceuticals Inc. 1,2-benzisoxazol-3-yl compounds
US20090006902A1 (en) * 2007-06-29 2009-01-01 International Business Machines Corporation Methods, systems, and computer program products for reporting fru failures in storage device enclosures
US8119632B2 (en) 2007-08-10 2012-02-21 Cortex Pharmaceuticals, Inc. Bicyclic amide derivatives for enhancing glutamatergic synaptic responses
US8263591B2 (en) 2007-08-10 2012-09-11 Cortex Pharmaceuticals, Inc. Bicyclic amides for enhancing glutamatergic synaptic responses
US8071914B2 (en) * 2007-12-26 2011-12-06 Noboru Oshima Heating apparatus
GB0806527D0 (en) 2008-04-11 2008-05-14 Astex Therapeutics Ltd Pharmaceutical compounds
WO2010087980A2 (en) * 2009-02-02 2010-08-05 Cortex Pharmaceuticals, Inc. Bicyclic amide derivatives for the treatment of respiratory depression
PT105083A (pt) 2009-04-28 2011-07-25 Univ De Coimbra Processo para cultura de células estaminais neurais baseado nas ampacinas e/ou outros moduladores de receptores glutamatérgicos ionotrópicos, composições e seu uso em condições do sistema nervoso central
WO2011109398A2 (en) 2010-03-02 2011-09-09 President And Fellows Of Harvard College Methods and compositions for treatment of angelman syndrome and autism spectrum disorders
US9700596B2 (en) 2011-03-04 2017-07-11 The Regents Of The University Of California Locally released growth factors to mediate motor recovery after stroke
US8822464B2 (en) 2011-11-28 2014-09-02 Boehringer Ingelheim International Gmbh N-aryl-piperazine derivatives and their use as positive allosteric modulators of mGluR5 receptors
US8741892B2 (en) * 2011-12-05 2014-06-03 Boehringer Ingelheim International Gmbh Compounds
US8796467B2 (en) 2011-12-13 2014-08-05 Boehringer Ingelheim International Gmbh Compounds
US8846948B2 (en) 2011-12-13 2014-09-30 Boehringer Ingelheim International Gmbh Compounds
US8716277B2 (en) 2011-12-14 2014-05-06 Boehringer Ingelheim International Gmbh Substituted imidazole compounds useful as positive allosteric modulators of mGlu5 receptor activity
US8937176B2 (en) 2011-12-14 2015-01-20 Boehringer Ingelheim International Gmbh Compounds
US8883789B2 (en) 2011-12-14 2014-11-11 Boehringer Ingelheim International Gmbh Piperazine derivatives and their use as positive allosteric modulators of mGluR5 receptors
US8889677B2 (en) 2012-01-17 2014-11-18 Boehringer Ingellheim International GmbH Substituted triazoles useful as mGlu5 receptor modulators
ES2673872T3 (es) 2012-06-05 2018-06-26 The Board Of Trustees Of The Leland Stanford Junior University Mimético del péptido NCAM para su uso en el tratamiento de trastorno de depresión mayor
UA127357C2 (uk) 2018-04-18 2023-07-26 Констеллатіон Фармацеутікалс, Інк. Модулятори метилмодифікуючих ферментів, композиції та їх використання
CA3100977A1 (en) 2018-05-21 2019-11-28 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8908085D0 (en) * 1989-04-11 1989-05-24 Lundbeck & Co As H New therapeutic use
US5312819A (en) * 1990-08-20 1994-05-17 Sandoz Ltd. Pharmaceutical compositions comprising clozapine and a radical scavenger
US5447948A (en) * 1992-05-07 1995-09-05 Yale University Dopamine and noradrenergic reuptake inhibitors in treatment of schizophrenia
GB9507230D0 (en) * 1995-04-07 1995-05-31 Inst Of Psychiatry Novel method
US5650409A (en) * 1995-06-02 1997-07-22 Cortex Pharmaceuticals, Inc. Benzoyl piperidines/pyrrolidines for enhancing synaptic response
US5773434A (en) * 1995-08-30 1998-06-30 Gary A. Rogers Facilitation of AMPA receptor-mediated synaptic transmission in brain as a treatment for schizophrenia
US5736543A (en) * 1996-04-03 1998-04-07 The Regents Of The University Of California Benzoxazines for enhancing synaptic response

Also Published As

Publication number Publication date
DE69833451D1 (de) 2006-04-20
DE69833451T2 (de) 2006-09-28
HK1030338A1 (en) 2001-05-04
CN1281335A (zh) 2001-01-24
CA2306817A1 (en) 1999-05-06
ATE317226T1 (de) 2006-02-15
WO1999021422A1 (en) 1999-05-06
EP1026950A4 (en) 2004-07-07
US6166008A (en) 2000-12-26
DK1026950T3 (da) 2006-06-26
EP1026950B1 (en) 2006-02-08
BR9814106A (pt) 2000-10-03
PT1026950E (pt) 2006-06-30
AU1365899A (en) 1999-05-17
ES2258825T3 (es) 2006-09-01
EP1026950A1 (en) 2000-08-16
AU745641B2 (en) 2002-03-28
JP2001520978A (ja) 2001-11-06

Similar Documents

Publication Publication Date Title
CY1105557T1 (el) Θεραπεια της σχιζοφρενειας με αμπακινες και νευροληπτικα φαρμακα
CY1115759T1 (el) Αντιβιοτικες συνθεσεις για θεραπεια του οφθαλμου
EE200200682A (et) Piperasiini derivaadid ja nende kasutamine põletikuvastaste vahenditena
BRPI0412262A (pt) derivados de azepina como agentes farmacêuticos
CY1105879T1 (el) Αζαδικυκλο παραγωγα ως ανταγωνιστες μουσκαρινικου υποδοχεα
CO4930259A1 (es) Derivados 6,6-heterobiciclicos sustituidos y composiciones farmaceuticas que los contienen
ES2161290T3 (es) Derivados de quinazolina.
DK1196397T3 (da) Metabotrope glutamatreceptorantagonister og anvendelse deraf til behandling af sygdomme i centralnervesystemet
PT896533E (pt) Pentafluorobenzenosulfonamidas e analogos
CY1106276T1 (el) Παραγωγα υποκατεστημενου φαινυλπροπιονικου οξεος ως ανταγωνιστες σε υποδοχεις αλφα που ενepγοποιουνται απο παραγοντες που επαγουν τον πολλαπλασιασμο των ανθρωπινων υπepοξεισωματων (ppar)
NO2005015I2 (no) Terapeutisk aktiv forbindelse preparat inneholdende forbindelsen samt den anvendelse
PE20020521A1 (es) Compuestos heterociclicos sustituidos para tratar la resistencia a multiples drogas
CY1115580T1 (el) Συνθεση και αντι-ιικη δραστηριοτητα των υποκατεστημενων παραγωγων αζαϊνδολοοξικης πιπεραζινης
CY1106645T1 (el) Παραγωγα 1,2,4 τριαμινοβενζολης χρησιμα για τη θεραπευτικη αντιμετωπιση διαταραχων του κεντρικου νευρικου συστηματος
DE60037578D1 (de) Verwendung von triacetyluridin zur behandlung von mitochondrialen erkrankungen
CO4910133A1 (es) Antagonistas de 5-h[1f]
TR200103460T2 (tr) 5-Fenil-pirimidin türevleri
FI963294A0 (fi) Naftyyliamidit keskushermostoaineina
SE9702564D0 (sv) New compounds
IS5352A (is) Ný efnasambönd
ATE223399T1 (de) Quinazolin-4-on ampa antagonisten
AR018162A1 (es) Pirroles substituidos, composicion farmaceutica y el uso de los mismos para la preparacion de dicha composicion farmaceutica
TR200103457T2 (tr) 4-Fenil-Pirimidin Türevleri.
PT870761E (pt) Derivados de tiocolchicina com actividades anti-inflamatoria e relaxante muscular
DK0431579T3 (da) Substituerede cyclohexener som midler med virkning på centralnervesystemet